A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Inclusion Criteria: * Participant must have completed Study M13-740 through Week 52. * If female, participant must be postmenopausal, surgically sterile or on using a birth control method. Exclusion Criteria: * For any reason participant is considered by the investigator to be an unsuitable candidate * Female participant with a positive pregnancy test at Baseline or who is considering becoming pregnant during the study. * Participant is not in compliance with prior and concomitant medication requirements and procedures throughout Study M13-740.